0000899243-21-035843.txt : 20210914 0000899243-21-035843.hdr.sgml : 20210914 20210914173029 ACCESSION NUMBER: 0000899243-21-035843 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210910 FILED AS OF DATE: 20210914 DATE AS OF CHANGE: 20210914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KLASKIN CHRISTINE M CENTRAL INDEX KEY: 0001288123 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-29089 FILM NUMBER: 211253300 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGENUS INC CENTRAL INDEX KEY: 0001098972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061562417 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-674-4410 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: ANTIGENICS INC /DE/ DATE OF NAME CHANGE: 19991115 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-10 0 0001098972 AGENUS INC AGEN 0001288123 KLASKIN CHRISTINE M C/O AGENUS INC. 3 FORBES ROAD LEXINGTON MA 02421 0 1 0 0 PFO & PAO Common Stock 2021-09-10 4 M 0 16563 3.36 A 104176 D Common Stock 2021-09-10 4 S 0 11120 6.50 D 93056 D Stock Option, right to buy 3.36 2021-09-10 4 M 0 16563 0.00 D 2011-12-14 2021-09-14 Common Stock 16563 0 D The options subject to the transaction reported on this Form 4 would have expired on September 14, 2021. The number of shares beneficially owned by the reporting person does not reflect 998 shares that were incorrectly reported on prior Form 4s. Represents sales of shares, as a consequence of the exercise of options, to cover Federal, state and local tax withholding requirements and the exercise price payment related to the option exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.47 to $6.52. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Christine M. Klaskin 2021-09-14